Then a test for identification of a germline heterozygous pathogenic variant in SMARCA4 or SMARCB1 by molecular genetic testing is indicated, at any age, in all cases of ATRT diagnosis (10–12). This evidence concerns the gene SMARCB1 and atypical teratoid rhabdoid tumor.